Home >> Top News >> PreludeDx unveils predictive assay for DCIS

PreludeDx unveils predictive assay for DCIS

Print Friendly, PDF & Email

Jan. 16, 2018PreludeDx announced in an oral presentation at the San Antonio Breast Cancer Symposium, held in December, the results from the SweDCIS randomized trial. The results confirmed that DCISionRT, the DCIS Test, predicts which patients with ductal carcinoma in situ will benefit from radiation therapy after breast conserving surgery.

The results, shared by SweDCIS principal investigator, Fredrik Wärnberg, MD, PhD, associate professor of surgery at Uppsala University, demonstrated that the DCISionRT test accurately stratified patients from the landmark trial into two groups: 1) a low-risk group that did not benefit from radiation therapy and 2) an elevated-risk group with a highly significant nine percent absolute benefit from radiation therapy. According to Rakesh Patel, MD, breast cancer radiation oncologist and medical director of breast cancer services at Good Samaritan Hospital, Los Gatos, Calif., “The use of DCISionRT in this randomized trial set demonstrated twice the benefit of radiation compared to all other previous DCIS trials investigating radiation therapy benefit. This is big news to radiation oncologists and surgeons worldwide and will impact the way DCIS is managed moving forward.”

PreludeDx is a leading personalized breast cancer diagnostics company. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient’s treatment decision. Its mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the health care system.

More top news